Abstract
Myeloid-derived suppressor cells (MDSC) play a significant role in tumor-induced immune suppression. Targeting their function could improve antitumor therapies. Previously, we demonstrated that phosphodiesterase 5 (PDE5) inhibition in MDSCs augmented antitumor immunity in murine models. Here, we show how the addition of the PDE5 inhibitor, tadalafil, in a patient with end-stage relapsed/refractory multiple myeloma reduced MDSC function and generated a dramatic and durable antimyeloma immune and clinical response. Strategies targeting MDSC function with PDE5 inhibitors represent a novel approach that can augment the efficacy of tumor-directed therapies.
Original language | English (US) |
---|---|
Pages (from-to) | 725-731 |
Number of pages | 7 |
Journal | Cancer Immunology Research |
Volume | 2 |
Issue number | 8 |
DOIs | |
State | Published - Aug 1 2014 |
Externally published | Yes |
ASJC Scopus subject areas
- General Medicine